| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 88 | 2024 | 3000 | 15.190 |
Why?
|
| Mastectomy | 48 | 2023 | 245 | 14.680 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2022 | 158 | 7.480 |
Why?
|
| Carcinoma, Lobular | 18 | 2019 | 81 | 6.130 |
Why?
|
| Mastectomy, Segmental | 18 | 2023 | 101 | 4.160 |
Why?
|
| Surgeons | 11 | 2023 | 247 | 3.880 |
Why?
|
| Mammaplasty | 10 | 2023 | 109 | 3.150 |
Why?
|
| Prophylactic Mastectomy | 8 | 2020 | 13 | 2.940 |
Why?
|
| Neoadjuvant Therapy | 8 | 2019 | 373 | 2.690 |
Why?
|
| Neoplasm Staging | 25 | 2019 | 2001 | 2.570 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 112 | 2.560 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2022 | 115 | 2.390 |
Why?
|
| Cancer Care Facilities | 4 | 2023 | 29 | 2.140 |
Why?
|
| Quality Indicators, Health Care | 5 | 2021 | 146 | 2.090 |
Why?
|
| Lymph Node Excision | 10 | 2021 | 220 | 2.030 |
Why?
|
| Receptors, Estrogen | 10 | 2022 | 393 | 2.000 |
Why?
|
| Female | 91 | 2024 | 46011 | 1.990 |
Why?
|
| Surgical Oncology | 4 | 2020 | 27 | 1.970 |
Why?
|
| Middle Aged | 66 | 2024 | 25863 | 1.950 |
Why?
|
| Sentinel Lymph Node Biopsy | 12 | 2021 | 72 | 1.950 |
Why?
|
| Radiation Oncology | 3 | 2021 | 121 | 1.930 |
Why?
|
| Databases, Factual | 18 | 2018 | 850 | 1.840 |
Why?
|
| Prognosis | 25 | 2020 | 3773 | 1.830 |
Why?
|
| Accreditation | 3 | 2019 | 61 | 1.820 |
Why?
|
| Practice Guidelines as Topic | 7 | 2019 | 1043 | 1.720 |
Why?
|
| Aged | 52 | 2024 | 19077 | 1.680 |
Why?
|
| Aged, 80 and over | 34 | 2023 | 6777 | 1.610 |
Why?
|
| Guideline Adherence | 4 | 2018 | 229 | 1.610 |
Why?
|
| Follow-Up Studies | 21 | 2020 | 3657 | 1.580 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2020 | 1363 | 1.560 |
Why?
|
| Humans | 101 | 2024 | 89063 | 1.530 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 485 | 1.490 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 296 | 1.480 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2020 | 5 | 1.430 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2024 | 192 | 1.420 |
Why?
|
| Mastectomy, Subcutaneous | 2 | 2022 | 8 | 1.390 |
Why?
|
| Nipples | 6 | 2022 | 37 | 1.350 |
Why?
|
| Adult | 47 | 2024 | 26507 | 1.330 |
Why?
|
| Thoracic Wall | 2 | 2018 | 25 | 1.240 |
Why?
|
| Receptor, ErbB-2 | 5 | 2019 | 245 | 1.220 |
Why?
|
| Lymph Nodes | 4 | 2018 | 548 | 1.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 2552 | 1.180 |
Why?
|
| United States | 28 | 2024 | 6955 | 1.170 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 599 | 1.140 |
Why?
|
| Breast Diseases | 2 | 2022 | 100 | 1.130 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 167 | 1.100 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 576 | 1.090 |
Why?
|
| Ergonomics | 3 | 2022 | 22 | 1.080 |
Why?
|
| Breast Neoplasms, Male | 2 | 2023 | 31 | 1.060 |
Why?
|
| Combined Modality Therapy | 8 | 2021 | 1710 | 1.050 |
Why?
|
| Decision Making | 4 | 2019 | 665 | 1.030 |
Why?
|
| Breast | 6 | 2021 | 292 | 1.000 |
Why?
|
| Axilla | 11 | 2021 | 104 | 0.990 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 1543 | 0.980 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 174 | 0.980 |
Why?
|
| Neoplasms, Second Primary | 3 | 2017 | 260 | 0.970 |
Why?
|
| Survival Rate | 12 | 2018 | 1889 | 0.960 |
Why?
|
| Retrospective Studies | 24 | 2024 | 9003 | 0.950 |
Why?
|
| Surveys and Questionnaires | 8 | 2023 | 2612 | 0.920 |
Why?
|
| Qualitative Research | 2 | 2024 | 291 | 0.890 |
Why?
|
| Attitude of Health Personnel | 4 | 2023 | 643 | 0.890 |
Why?
|
| Young Adult | 15 | 2024 | 6288 | 0.870 |
Why?
|
| Carcinoma | 2 | 2017 | 443 | 0.850 |
Why?
|
| Brachytherapy | 2 | 2014 | 121 | 0.850 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 410 | 0.820 |
Why?
|
| Patient Satisfaction | 5 | 2024 | 461 | 0.810 |
Why?
|
| Organ Sparing Treatments | 2 | 2019 | 46 | 0.800 |
Why?
|
| Medical Overuse | 2 | 2019 | 36 | 0.800 |
Why?
|
| Neoplasm Grading | 10 | 2018 | 372 | 0.760 |
Why?
|
| Oncologists | 1 | 2021 | 36 | 0.730 |
Why?
|
| Quality of Health Care | 3 | 2018 | 385 | 0.730 |
Why?
|
| Burnout, Professional | 1 | 2021 | 100 | 0.660 |
Why?
|
| Lymphatic Metastasis | 7 | 2018 | 502 | 0.660 |
Why?
|
| Age Factors | 9 | 2018 | 1867 | 0.660 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 156 | 0.650 |
Why?
|
| Stereotaxic Techniques | 1 | 2019 | 80 | 0.640 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2015 | 7 | 0.640 |
Why?
|
| Patient Selection | 6 | 2019 | 682 | 0.630 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 68 | 0.630 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.620 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 304 | 0.620 |
Why?
|
| Reoperation | 5 | 2015 | 598 | 0.610 |
Why?
|
| Patient Care | 1 | 2019 | 102 | 0.600 |
Why?
|
| Radiography, Interventional | 1 | 2019 | 154 | 0.600 |
Why?
|
| Genes, BRCA2 | 3 | 2016 | 161 | 0.600 |
Why?
|
| Patient Transfer | 1 | 2018 | 94 | 0.600 |
Why?
|
| Consensus | 2 | 2016 | 356 | 0.590 |
Why?
|
| Genes, BRCA1 | 3 | 2016 | 192 | 0.590 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 18 | 0.590 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2017 | 257 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 36 | 0.570 |
Why?
|
| Radiotherapy, Conformal | 1 | 2017 | 84 | 0.570 |
Why?
|
| Patient Preference | 4 | 2019 | 108 | 0.550 |
Why?
|
| Logistic Models | 7 | 2017 | 1212 | 0.550 |
Why?
|
| Adolescent | 9 | 2024 | 9237 | 0.540 |
Why?
|
| Postoperative Complications | 7 | 2016 | 2275 | 0.530 |
Why?
|
| Societies, Medical | 2 | 2019 | 570 | 0.520 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 531 | 0.500 |
Why?
|
| Pandemics | 6 | 2023 | 771 | 0.500 |
Why?
|
| Prospective Studies | 8 | 2022 | 4273 | 0.490 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 147 | 0.480 |
Why?
|
| Quality of Life | 4 | 2019 | 1662 | 0.470 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1706 | 0.450 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 359 | 0.440 |
Why?
|
| Elective Surgical Procedures | 1 | 2014 | 126 | 0.430 |
Why?
|
| Receptors, Notch | 2 | 2010 | 123 | 0.410 |
Why?
|
| Length of Stay | 3 | 2015 | 732 | 0.410 |
Why?
|
| Melanoma | 2 | 2009 | 467 | 0.410 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 176 | 0.400 |
Why?
|
| Skin Neoplasms | 2 | 2009 | 579 | 0.380 |
Why?
|
| Workload | 2 | 2022 | 129 | 0.370 |
Why?
|
| Operating Rooms | 2 | 2022 | 129 | 0.360 |
Why?
|
| Receptor, Notch1 | 2 | 2010 | 94 | 0.360 |
Why?
|
| Patient Readmission | 1 | 2014 | 351 | 0.360 |
Why?
|
| Registries | 1 | 2014 | 778 | 0.350 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2008 | 4 | 0.330 |
Why?
|
| Patients | 2 | 2023 | 102 | 0.330 |
Why?
|
| Socioeconomic Factors | 3 | 2016 | 582 | 0.310 |
Why?
|
| Quality Control | 2 | 2019 | 117 | 0.300 |
Why?
|
| Breast Implantation | 3 | 2016 | 13 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2010 | 665 | 0.290 |
Why?
|
| Calcinosis | 1 | 2008 | 230 | 0.290 |
Why?
|
| Incidence | 3 | 2023 | 1592 | 0.280 |
Why?
|
| Pilot Projects | 3 | 2019 | 865 | 0.270 |
Why?
|
| SEER Program | 3 | 2017 | 197 | 0.270 |
Why?
|
| Risk Factors | 6 | 2019 | 5466 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 833 | 0.270 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 988 | 0.260 |
Why?
|
| Risk Assessment | 4 | 2020 | 2290 | 0.250 |
Why?
|
| Health Care Surveys | 2 | 2018 | 280 | 0.250 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 848 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3443 | 0.240 |
Why?
|
| Referral and Consultation | 2 | 2019 | 341 | 0.240 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 54 | 0.230 |
Why?
|
| Male | 9 | 2024 | 42251 | 0.230 |
Why?
|
| Biopsy | 3 | 2014 | 1182 | 0.220 |
Why?
|
| Self Concept | 1 | 2023 | 132 | 0.220 |
Why?
|
| Time Factors | 5 | 2016 | 5320 | 0.210 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 470 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2018 | 2863 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1429 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 261 | 0.180 |
Why?
|
| Mammography | 2 | 2017 | 471 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2020 | 60 | 0.170 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 251 | 0.170 |
Why?
|
| Health Resources | 1 | 2020 | 81 | 0.170 |
Why?
|
| Body Image | 1 | 2019 | 78 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 65 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1067 | 0.170 |
Why?
|
| Triage | 1 | 2020 | 111 | 0.170 |
Why?
|
| Fear | 1 | 2019 | 79 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2020 | 187 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 334 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2018 | 8203 | 0.160 |
Why?
|
| Breast Implants | 2 | 2016 | 25 | 0.160 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 121 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 295 | 0.160 |
Why?
|
| Anxiety | 1 | 2021 | 308 | 0.160 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Video Recording | 1 | 2019 | 203 | 0.160 |
Why?
|
| Databases as Topic | 1 | 2018 | 94 | 0.160 |
Why?
|
| Emotions | 1 | 2021 | 349 | 0.150 |
Why?
|
| Patient Participation | 1 | 2019 | 224 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 185 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2018 | 230 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2018 | 160 | 0.140 |
Why?
|
| Heterozygote | 2 | 2016 | 373 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2018 | 684 | 0.140 |
Why?
|
| Sleep | 1 | 2021 | 452 | 0.140 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 83 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 329 | 0.140 |
Why?
|
| Surgical Wound Infection | 2 | 2015 | 201 | 0.130 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 179 | 0.130 |
Why?
|
| Esthetics | 1 | 2016 | 45 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2016 | 63 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 472 | 0.130 |
Why?
|
| Molecular Typing | 1 | 2015 | 17 | 0.130 |
Why?
|
| Comprehension | 1 | 2016 | 80 | 0.130 |
Why?
|
| Europe | 1 | 2016 | 321 | 0.130 |
Why?
|
| Pharyngectomy | 1 | 2015 | 8 | 0.130 |
Why?
|
| Remission Induction | 1 | 2017 | 740 | 0.130 |
Why?
|
| Neoplasms | 2 | 2022 | 3035 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2016 | 216 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1796 | 0.120 |
Why?
|
| Physicians | 2 | 2019 | 689 | 0.120 |
Why?
|
| Counseling | 1 | 2016 | 163 | 0.120 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 53 | 0.120 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 421 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 309 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1108 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1855 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 981 | 0.120 |
Why?
|
| Adipokines | 1 | 2013 | 17 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 461 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2014 | 159 | 0.110 |
Why?
|
| Receptor, Notch4 | 2 | 2010 | 5 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 132 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 859 | 0.110 |
Why?
|
| Fatty Acids | 1 | 2013 | 134 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 304 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2015 | 249 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 159 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2013 | 259 | 0.090 |
Why?
|
| Models, Biological | 1 | 2018 | 1763 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 424 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2752 | 0.090 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2010 | 13 | 0.090 |
Why?
|
| Jagged-1 Protein | 1 | 2010 | 13 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 1063 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1265 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 1 | 2010 | 121 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 181 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2347 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2008 | 222 | 0.080 |
Why?
|
| Receptor Cross-Talk | 1 | 2008 | 34 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2009 | 226 | 0.080 |
Why?
|
| Quality Improvement | 2 | 2022 | 447 | 0.080 |
Why?
|
| Hemostatics | 1 | 2008 | 57 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 71 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 415 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 233 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 1096 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 360 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2008 | 152 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 160 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 171 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 179 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 966 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 901 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2011 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1214 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2014 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1215 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 1715 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 306 | 0.050 |
Why?
|
| Mutation | 1 | 2014 | 4132 | 0.050 |
Why?
|
| Organizational Innovation | 1 | 2020 | 41 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 1057 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2023 | 537 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 306 | 0.040 |
Why?
|
| Fees and Charges | 1 | 2018 | 14 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2018 | 29 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 17 | 0.040 |
Why?
|
| Mass Screening | 1 | 2022 | 636 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 147 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 337 | 0.040 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 147 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 308 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1423 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 781 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1650 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 476 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 295 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 116 | 0.030 |
Why?
|
| Communication | 1 | 2018 | 457 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2015 | 166 | 0.030 |
Why?
|
| Lipase | 1 | 2013 | 20 | 0.030 |
Why?
|
| Serpins | 1 | 2013 | 31 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 343 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2013 | 63 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 657 | 0.030 |
Why?
|
| Leptin | 1 | 2013 | 102 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 625 | 0.030 |
Why?
|
| Eye Proteins | 1 | 2013 | 128 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 66 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 96 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 70 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 354 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 948 | 0.020 |
Why?
|
| Sepsis | 1 | 2015 | 319 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 771 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 41 | 0.020 |
Why?
|
| Estradiol | 1 | 2008 | 250 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 470 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 814 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 557 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1087 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 11737 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 27317 | 0.000 |
Why?
|